1. Definition

Creatine kinase (CK), also called creatine phosphokinase (CPK), is an intracellular enzyme that catalyzes the reversible conversion:Creatine+ATP↔Phosphocreatine+ADPCreatine + ATP \leftrightarrow Phosphocreatine + ADPCreatine+ATP↔Phosphocreatine+ADP

This reaction is crucial for energy storage and rapid regeneration of ATP, especially in muscle and brain tissues.

---

2. Location in Body

CK is present mainly in tissues with high energy demand:

Tissue	CK concentration
Skeletal muscle	Highest
Cardiac muscle	High
Brain	Moderate
Smooth muscle	Low

Because CK is intracellular, serum CK rises when cell membrane damage occurs.

---

3. CK Isoenzymes

CK exists in three isoenzymes, formed by combinations of M (muscle) and B (brain) subunits.

Isoenzyme	Structure	Major Source	Clinical significance
CK-MM	M + M	Skeletal muscle	Muscle injury, rhabdomyolysis
CK-MB	M + B	Cardiac muscle	Myocardial injury
CK-BB	B + B	Brain, smooth muscle	CNS injury

Distribution

• CK-MM: ~95–100% of total CK in normal serum
• CK-MB: <5% normally
• CK-BB: normally absent in serum

---

4. Normal Values

Normal ranges vary by lab.

Typical reference:

Group	CK (U/L)
Adult male	50–200
Adult female	40–150
Children	Higher than adults
Neonates	Can be very high after birth

---

5. Causes of Elevated CK

A. Skeletal Muscle Disorders

Most common cause.

Examples:

• Muscular dystrophy (e.g., Duchenne muscular dystrophy)
• Inflammatory myopathies
  • Polymyositis
  • Dermatomyositis
• Trauma
• Intramuscular injections
• Vigorous exercise

---

B. Rhabdomyolysis

Massive CK elevation.

Causes:

• Crush injury
• Drugs (statins)
• Heat stroke
• Severe infections

CK may rise >5000–10,000 U/L.

---

C. Cardiac Causes

CK-MB rises in myocardial injury.

Example:

• Myocardial Infarction

However, CK-MB is now largely replaced by troponins.

---

D. Neurologic Disorders

CK-BB may increase in:

• Stroke
• Brain trauma
• Seizures

Example:

• Stroke

---

E. Other Causes

• Hypothyroidism
• Alcohol abuse
• Surgery
• Prolonged immobilization
• Severe infections

---

6. CK in Myocardial Infarction

Historically important marker.

Parameter	CK-MB
Rise	3–6 hours
Peak	12–24 hours
Normalization	48–72 hours

Used previously to detect reinfarction.

Now replaced mainly by troponin I/T.

---

7. CK in Pediatric Practice

Important uses:

Screening for muscular dystrophy

Very high CK in:

• Duchenne muscular dystrophy
• Becker muscular dystrophy

Levels may be 10–100× normal.

---

Evaluation of Hypotonia

Used when evaluating:

• floppy infant
• muscle weakness

---

Evaluation of Rhabdomyolysis

Symptoms:

• myalgia
• weakness
• dark urine (myoglobinuria)

---

8. Causes of Decreased CK

Rare clinical significance.

Seen in:

• Low muscle mass
• Chronic illness
• Pregnancy

---

9. Drugs Causing Elevated CK

Important clinically.

Examples:

Drug	Mechanism
Statins	Myopathy
Antipsychotics	Neuroleptic malignant syndrome
Corticosteroids	Muscle breakdown

Example condition:
Neuroleptic Malignant Syndrome

---

10. Investigation Panel When CK is Elevated

Test	Purpose
CK-MB	Cardiac source
Troponin	MI confirmation
AST / ALT	Muscle vs liver
LDH	Tissue injury
Serum myoglobin	Rhabdomyolysis
Urine myoglobin	Kidney injury

---

11. CK in Rhabdomyolysis Severity

CK level	Interpretation
<1000	Mild
1000–5000	Moderate

5000 | Severe muscle injury |
15000 | High risk of renal failure |

---

12. Clinical Pearls (Exam High-Yield)

• CK-MM → skeletal muscle injury
• CK-MB → cardiac muscle
• CK-BB → brain
• Duchenne muscular dystrophy → CK extremely high
• CK rises after muscle trauma/exercise
• CK-MB replaced by troponin in MI diagnosis

---

✅ One-line exam memory tip

“CK rises with muscle damage — skeletal (MM), cardiac (MB), brain (BB).”

1. Clinical Assessment

History

• Onset, duration, frequency, and number of ulcers
• Pain severity, triggers (trauma, stress, certain foods)
• Systemic symptoms: fever, diarrhea, joint pain, fatigue
• Family history of similar lesions
• Medications (NSAIDs, beta-blockers)
• Previous treatments and response

Examination

• Location: non-keratinized mucosa (buccal, labial, ventral tongue, floor of mouth)
• Size:
  • Minor (<1 cm) – most common
  • Major (>1 cm, deeper, may scar)
  • Herpetiform (multiple small ulcers)
• Number: single or multiple
• Appearance: round/oval, yellow-white pseudomembrane with erythematous halo
• Rule out: secondary causes (herpes simplex, trauma, systemic disease)

---

2. Investigations (If atypical or recurrent)

• Basic labs: CBC, iron studies, vitamin B12, folate (nutritional deficiencies)
• CRP/ESR: if systemic symptoms
• Serology: celiac disease (tTG-IgA), HIV (if risk factors)
• Biopsy: rare, only if persistent >3 weeks, atypical, or suspected malignancy
• Microbiology: rarely needed; ulcers are typically non-infectious

---

3. Classification

Type	Features	Management Focus
Minor	<1 cm, 1–5 lesions, heal 7–14 days	Symptomatic relief
Major	>1 cm, deep, persistent, may scar	Systemic therapy possible
Herpetiform	Multiple, small, coalescing, painful	Combination topical/systemic therapy

---

4. Management

A. General Measures

• Avoid triggers: spicy/acidic foods, trauma
• Good oral hygiene
• Avoid sodium lauryl sulfate in toothpaste
• Stress management
• Nutritional supplementation if deficient

B. Topical Therapy (First-line for minor ulcers)

• Topical corticosteroids:
  • Triamcinolone acetonide 0.1% in orabase
  • Fluocinonide 0.05% gel
• Topical anesthetics:
  • Lidocaine 2% gel for pain relief
• Protective agents:
  • Orabase, hydroxypropyl cellulose films

C. Systemic Therapy (For severe, recurrent, or major ulcers)

• Oral corticosteroids:
  • Prednisone short course (e.g., 30–60 mg/day tapering)
• Immunomodulators (refractory cases):
  • Colchicine, thalidomide, dapsone
• Address underlying systemic disease:
  • Nutritional deficiencies, IBD, Behçet’s disease, etc.

D. Adjunctive Therapy

• Antimicrobial mouth rinses: chlorhexidine gluconate
• Pain control: NSAIDs (if not contraindicated)
• Laser therapy (experimental for pain reduction and healing)

---

5. Follow-Up

• Minor ulcers: usually self-limiting; review if >3 weeks
• Recurrent or major ulcers: monitor frequency, severity, and response to therapy
• Evaluate for systemic disease if persistent or atypical

---

Introduction

The APGAR score is a rapid method to assess the health status of a newborn immediately after birth.
It was introduced in 1952 by Dr. Virginia Apgar, an American anesthesiologist, to provide an objective and standardized evaluation.

The score is based on five parameters, each evaluated at 1 minute and 5 minutes after birth, with each parameter scored from 0 to 2. The maximum score is 10.

---

APGAR Parameters

Letter	Parameter	0 Points	1 Point	2 Points
A	Appearance (Skin Color)	Entire body bluish/cyanotic	Pink body, bluish hands & feet (acrocyanosis)	Entire body pink
P	Pulse (Heart Rate)	Absent	< 100 bpm	≥ 100 bpm
G	Grimace (Reflex Response)	No response to stimulation	Grimace only	Cough, sneeze, or cry
A	Activity (Muscle Tone)	Limbs extended (flaccid)	Some flexion of limbs	Active motion, full flexion
R	Respiratory Effort	Absent	Weak cry or labored breathing	Strong cry, good breathing

---

Interpreting the APGAR Score

• 7–10: Normal, healthy newborn
• 4–6: Mild depression (needs observation and possibly mild intervention)
• 0–3: Severe depression (needs urgent medical attention)

---

When to Measure

• 1-minute APGAR: Reflects the newborn’s condition at birth and initial adaptation to the environment.
• 5-minute APGAR: Evaluates the effectiveness of ongoing care and resuscitation efforts.
• If the 5-minute score is < 7, assessment should be repeated every 5 minutes up to 20 minutes.

---

Practical Note for Delivery Rooms

• Look & Listen: Appearance, activity, respiratory effort
• Feel: Heart rate, reflex response (grimace)

This quick check can be done within seconds and helps guide immediate care for the newborn.

---

Summary:
The APGAR score remains one of the simplest and most effective tools for assessing newborn well-being. It does not predict long-term outcomes but is essential for guiding immediate care and determining if urgent intervention is required.

---

---

1. Definition

A Vaccine Vial Monitor (VVM) is a small thermochromic label placed on a vaccine vial, ampoule, or dropper to monitor cumulative heat exposure over time.

• Purpose: Helps ensure that vaccines have not been damaged by excessive heat during storage or transport in the cold chain.
• Function: Color changes irreversibly with time and temperature.

---

2. Components & Principle

• Center Square: Heat-sensitive material that darkens progressively with heat exposure.
• Outer Reference Ring: Fixed color for comparison.
• Working Principle:
  • Heat causes a chemical reaction in the center square.
  • The higher the temperature, the faster the change.
  • Based on Arrhenius kinetics—reaction rate doubles with ~10 °C rise in temperature.

---

3. Reading a VVM

• Acceptable: If center square is lighter than outer ring → vaccine usable.
• Discard: If center square is same or darker than outer ring → vaccine compromised.

---

4. VVM Types & Vaccine Shelf Life

WHO assigns VVM categories depending on vaccine heat stability:

VVM Type	Time to end-point at 37 °C	Examples
VVM30	≥ 30 days	Oral polio (OPV), Hep B
VVM14	≥ 14 days	DTP, Pentavalent
VVM7	≥ 7 days	Rotavirus
VVM2	≥ 2 days	Certain lyophilized vaccines (e.g., measles, BCG before reconstitution)

---

5. Storage & Handling Notes for Pediatric Use

• Check VVM before every use—especially in outreach/immunization camps.
• Do not refrigerate below recommended temperature just to “reset” VVM—it’s irreversible.
• VVM is not a freeze indicator—separate freeze indicators are used for freeze-sensitive vaccines (e.g., DTP, Hep B).
• Post-reconstitution: VVM is invalid for multi-dose lyophilized vaccines—time limit per WHO multi-dose policy applies.

---

6. Field Significance in Pediatrics

• Ensures safe vaccines for children in peripheral settings where cold chain breaches are common.
• Reduces wastage by allowing use of vaccines that have been out of refrigeration but still within VVM limit.
• Prevents administration of heat-damaged vaccines, which could cause reduced immunogenicity without visible signs.

---

7. Limitations

• Cannot detect freezing damage.
• Not a substitute for proper cold chain monitoring (data loggers, ice packs, cold boxes).
• Only indicates cumulative heat exposure—not precise real-time temperature.

Space travel is a marvel of human ingenuity, a daring leap into the unknown. But beyond the sleek spacecraft and zero-gravity acrobatics, astronauts face a very human challenge: their own biology. For female astronauts, one of the lesser-known but fascinating aspects of spaceflight is their use of birth control pills.

But wait—why would astronauts, who are laser-focused on their mission and in an environment where pregnancy isn’t exactly a concern, take birth control in space? The answer is more intriguing than you might think.

---

Periods in Space: A Problem NASA Didn’t Expect

When NASA first sent women to space in the 1980s, they had to ask a question they’d never considered before: what happens to the menstrual cycle in microgravity? The answer wasn’t entirely clear. Would periods become irregular? More painful? Or would the lack of gravity somehow prevent menstruation altogether?

To avoid unpleasant surprises, most female astronauts choose to suppress their periods entirely—and that’s where birth control pills come in.

---

The Challenges of Menstruation in Microgravity

Imagine trying to change a tampon in zero gravity. In a spaceship where every drop of liquid behaves unpredictably, dealing with menstrual blood can be messy, uncomfortable, and impractical. Plus, water for personal hygiene is limited, and every ounce of cargo—including sanitary products—adds weight to the mission.

By using birth control pills continuously (skipping the placebo week), astronauts can pause their menstrual cycle for months at a time. No periods, no hassle.

---

Are There Other Options?

Yes! Some astronauts opt for long-acting contraceptives like the hormonal IUD or implants, which can prevent periods for years. These options eliminate the need to take daily pills, which could be tricky in space due to strict schedules and potential nausea from microgravity.

---

But Is It Safe?

Absolutely. Many women on Earth use birth control for non-contraceptive reasons, like reducing cramps or managing conditions like endometriosis. Studies show that long-term use of birth control pills or other hormonal methods is generally safe, even in space.

NASA and other space agencies carefully monitor the health of astronauts, ensuring that any medication—birth control included—is safe for long-duration missions.

---

The Future: What About Mars Missions?

With upcoming plans for deep-space travel, including missions to Mars that could last years, managing reproductive health becomes even more critical. Scientists are exploring better hormonal suppression methods and even potential ways to pause menstruation for extended periods without daily medication.

As we prepare for life beyond Earth, one thing is clear: human biology doesn’t stop in space, but science is making sure astronauts can focus on the stars—not their cycles.